Flaws and All, This Is a Start

Article

My thought is that it is good to move forward. No doubt there will be needed changes, but the status quo is broken.

Michael Glod, MD

My thought is that it is good to move forward. No doubt there will be needed changes, but the status quo is broken and as Roosevelt said during the depression, “Try something. Try anything. And if that doesn’t work, try something else.” Flaws and all, this is a start. Hopefully it won’t result in World War II between the political parties.

 

More on the Supreme Court Decision

Derek Raghavan
Bruce Minsky
Nora Janjan
Michael Glod
James B. Yu
Lawrence Wagman
Recent Videos
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Related Content
The rate of MRD negativity, defined as next-generation flow with a sensitivity of 10-5, at the end of consolidation was 74.8%.

Isa-KRd Yields Significant MRD Negativity in High-Risk NDMM Cytogenetic Subgroups

Tim Cortese
September 18th 2025
Article

MRD-negative remission was achieved in 74.8% of all patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling

Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling

Shaila Mulki, PhD, MDS;Seema Mavinapalla, MDS;Supriya Hulimane, MDS;Elizabeth Sojan, MDS;Deviprasad Nooji, MDS;Vidya Gowdappa Doddawad, MDS
September 18th 2025
Article

Enhancing patient adherence to follow-up care for leukoplakia through habit cessation counseling and patient information leaflets may reduce oral cancer risks.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.

Elranatamab Combo Yields Early Efficacy in Transplant-Ineligible NDMM

Russ Conroy
September 17th 2025
Article

Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.

Previously, in December 2024, CRB-701 was granted FTD by the FDA for relapsed/refractory metastatic cervical cancer.

FDA Grants Fast Track Designation to CRB-701 in Pretreated Recurrent HNSCC

Tim Cortese
September 17th 2025
Article

The next-generation ADC, CRB-701, demonstrated an emerging objective response rate of 57% in a subgroup of patients with HNSCC.